Cantargia granted patent in the UK for the medical use of IL1RAP modulators

Lund, Sweden 11 July 2012. Cantargia AB announced today that the UK Intellectual Property Office has granted a patent to Cantargia covering the medical use of agents in the treatment and diagnosis of neoplastic hematological disorders, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lympoblastic leukemia (ALL), myeloproliferative disorders (MPD) and myelodysplastic syndrome (MDS). All agents with specificity to bind to the interleukin-1 receptor accessory protein (IL1RAP) for such use are covered by the patent.

The company is currently in the lead identification phase and has generated a number of IL1RAP specific monoclonal antibodies which are being characterized. The concept of targeting IL1RAP has been validated both ex-vivo and in-vivo in models of human cancer.

About Cantargia AB
Cantargia AB is a research and development company based on an original discovery at Lund University. Cantargia is focused on developing a conceptually new therapy for the treatment of hematological malignancies (leukemia) by targeting IL1RAP, a unique cell-surface receptor on leukemic stem cells. The IL1RAP receptor has also been shown to be up-regulated in several solid tumors. Cantargia is currently evaluating the therapeutic potential in malignant melanoma.

Cantargia’s primary goal is to improve the lives of patients by developing antibody therapeutics with the potential to eliminate cancer stem cells that cause the disease.

For more information on Cantargia visit www.cantargia.com.